Jogeshwari, India
Jogeshwari, India

Time filter

Source Type

News Article | May 17, 2017
Site: www.prnewswire.com

The seven categories for 2017 are: Law Enforcement/Arson Dogs, sponsored by the K-9 Courage Program™ from Zoetis; Military Dogs, sponsored by the K-9 Courage Program from Zoetis; Therapy Dogs, sponsored by Chicken Soup for the Soul Pet Food, the official pet food of the 2017 Hero Dog Awards; Service Dogs, sponsored by Modern Dog magazine; Emerging Hero Dogs, a category that pays tribute to ordinary dogs who do extraordinary things, sponsored by Boehringer Ingelheim Animal Health, maker of NexGard® (afoxolaner) Chewables; Search and Rescue Dogs; and Guide/Hearing Dogs. Over the past six years, Americans have cast millions of votes for more than a thousand dogs, all seeking the coveted title of American Hero Dog. The program reaches more than one billion people each year and draws the support and participation of top celebrity dog lovers from all over the world. Hosts, judges, award presenters, and entertainment acts have included Katharine McPhee, Alison Sweeney, Bindi Irwin, Derek Hough, Michelle Beadle, Victoria Stilwell, Betty White, Whoopi Goldberg, Denise Richards, Gary Sinise, Burt Reynolds, Chelsea Handler, Martin Short, Jewel, Wilson Phillips, John Ondrasik, Carson Kressley, Miranda Lambert, Pauley Perrette, Kristen Chenoweth, Naomi Judd, Lori Loughlin, Lea Thompson, Eric Stonestreet, Fred Willard, Danica McKellar, Bailee Madison, and many, many more. "For thousands of years, mankind has had a special relationship with dogs, and the American Humane Hero Dog Awards are our way of honoring the best of our best friends," said Dr. Robin Ganzert, American Humane president and CEO. "This unique awards show celebrates the unbreakable human-animal bond, which has been a core part of our organization's mission since 1877." "The Hero Dog Awards recognize some of America's bravest heroes on both ends of the leash," said philanthropist and presenting sponsor Lois Pope. "From those who defend our country to those who help us heal, guide us, protect us, and help find the lost, every single contender exemplifies the courage and heroism we seek to spotlight in this campaign. Our goal is not only to honor these magnificent dogs but to inspire America to reflect on the outsized contributions that animals make in our lives each and every day." Here are brief descriptions, written by the hero dogs' owners/handlers: For more information about the 2017 American Humane Hero Dog Awards®, and to vote daily in the contest, please visit www.herodogawards.org. For more information on sponsorship opportunities email Mari Harner at marih@americanhumane.org  or call 1-800-227-4645. American Humane is the country's first national humane organization, founded in 1877. For more information, please visit www.americanhumane.org. To inquire about Hero Dog Awards sponsorship opportunities, please email Mari Harner at marih@americanhumane.org. About Lois Pope, The Lois Pope LIFE Foundation, Inc., and LIFE (Leaders in Furthering Education) As one of America's leading philanthropists, Lois Pope has positively impacted the lives of individuals at the local, national and international levels.  She has established three separate organizations dedicated to helping those in need.  These organizations are the Lois Pope LIFE Foundation, Inc., Leaders In Furthering Education (LIFE), and the Disabled Veterans' Life Memorial Foundation.  For more than 20 years she has been the driving force behind the Lois Pope LIFE Center at the University of Miami School of Medicine, The American Veterans Disabled for Life Memorial, and a groundbreaking new program with American Humane in Palm Beach County. Lois Pope has recently donated two Lois Pope Red Star Rescue Vehicles. Each rescue vehicle is a 50-foot long response unit, complete with a Ford F-350 truck and trailer, which is specifically designed and outfitted to provide an array of animal emergency services and cruelty responses within the region. Mrs. Pope recently saw the completion of a decade's long dream – the American Veterans Disabled for Life Memorial, which was dedicated by President Obama in Washington, DC on Sunday, October 5, 2014. The Memorial will forever stand as a reminder to the public and legislators of the courage and sacrifices of the four million living disabled veterans and all those who died before them for the need to be vigilant in assuring their support, as well as being aware of the human cost of war. A mother and a grandmother, Lois has trained for and completed five New York City Marathons. Hallmark Channel is Crown Media Family Networks' flagship 24-hour cable television network, distributed nationwide in high definition (HD) and standard definition (SD) to 89 million homes.  As the country's leading destination for quality family entertainment, Hallmark Channel delivers on the 100-year legacy of the Hallmark brand.  In addition to its signature new, original movies, the network features an ambitious lineup of other new, original content, including scripted primetime series, such as "Good Witch," "When Calls the Heart" and "Chesapeake Shores"; annual specials including "Kitten Bowl" and "Hero Dog Awards"; and a daily, two-hour lifestyle show, "Home & Family."  Additionally, Hallmark Channel is the exclusive home to world premiere presentations of the acclaimed Hallmark Hall of Fame franchise.  Dedicated to helping viewers celebrate life's special moments, Hallmark Channel also offers annual holiday programming franchises, including "Countdown to Christmas," "Countdown to Valentine's Day," "Summer Nights," "Fall Harvest" and "Winterfest."  Rounding out the network's diverse slate are some of television's most beloved comedies and series, including "The Golden Girls," "The Middle," "Last Man Standing," and "Frasier." For more information, please visit www.crownmediapress.com  Hallmark Channel on Social Media: Facebook, Twitter, Pinterest, YouTube Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here. Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com. About Chicken Soup for the Soul Pet Food Chicken Soup for the Soul understands the unique relationship between people and pets. Health conscious consumers have been feeding their cats and dogs Chicken Soup for the Soul wholesome and balanced, super premium pet food for over a decade. Holistic in nature, the entire line of products is made from only the finest ingredients: real meats (chicken, turkey, duck and salmon), fruits, vegetables and herbs. With no added corn, wheat, soy, artificial coloring, flavoring or preservatives, Chicken Soup for the Soul pet food is inspired by your love for pets, and promotes overall health and well-being for dogs and cats.  The products are proudly made in the USA, and feature rescued shelter pets on every bag. Core and grain-free formulas are available in independent pet specialty stores nationwide and online, with a new line of treats recently launched. A portion of all proceeds from the sale of Chicken Soup for the Soul pet food goes to help shelters and pets in need through Chicken Soup for the Soul's Fill a Bowl … Feed a Soul™ program. The program which was launched in association with the American Humane aims to provide a million meals to shelter pets in 2017. www.chickensouppets.com Modern Dog -- "the best dog magazine ever" and the #1 dog publication in North America -- is a must-read for dog lovers. Your source for the best ideas and solutions for life with dogs, Modern Dog features training tips, insight into your dog's behavior, the best gear, wellness, rescue, DIY how-tos, contests and more! A large part of Modern Dog's mission is to support rescue and the organizations that work tirelessly to help dogs in need. Find Modern Dog online -- www.moderndogmagazine.com -- on newsstands across North America, and on all major social platforms. Modern Dog, your guide to a better bond with your dog! To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/21-remarkable-canines-competing-to-become-americas-top-dog-300459579.html


ZAVENTEM, Bélgica--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) ha anunciado que la Comisión Europea ha concedido a la empresa una autorización para la comercialización de Cytopoint (lokivetmab), el primer tratamiento de anticuerpo monoclonal (mAb en sus siglas en inglés) aprobado en la Unión Europea para uso veterinario. Cytopoint está indicado para el tratamiento de los síntomas clínicos, incluidos los picores y la inflamación, asociados con la dermatitis atópica en perros de cualquier edad con un


ZAVENTEM, Belgio--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) oggi ha annunciato di avere ottenuto dalla Commissione Europea l’autorizzazione a commercializzare Cytopoint (lokivetmab), il primo anticorpo monoclonale (mAb) approvato per l’uso terapeutico nella pratica clinica veterinaria nell’Unione Europea. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare


ZAVENTEM, België--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) heeft vandaag bekendgemaakt dat de Europese Commissie het bedrijf een vergunning heeft gegeven voor het in handel brengen van Cytopoint (lokivetmab), de eerste in de EU goedgekeurde behandeling met een monoklonale antistof voor diergeneeskunde. Cytopoint is goedgekeurd voor de behandeling van de klinische symptomen verband houden met atopische dermatitis, zoals jeuk en ontstekingsreacties, bij honden van alle leeftijden die zwaarder zijn dan drie kilo. Cytopoint bestrijdt en neutraliseert canine interleukin-31 (cIL-31), een belangrijk eiwit dat jeuk veroorzaakt bij honden. Het medicijn wordt via injectie toegediend en zorgt voor snelle en langdurige verlossing van jeuk – het belangrijkste kenmerk van de allergische huidaandoening bij honden – en de ontstekingen en wonden die de ziekte veroorzaakt. Cytopoint draagt op de lange termijn bij aan een gezonder en beter leven voor honden die aan atopische dermatitis lijden en verlicht de frustraties en zorgen van hun baasjes. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.


News Article | May 5, 2017
Site: www.businesswire.com

ATLANTA--(BUSINESS WIRE)--Visioneering Technologies, Inc. (ASX: VTI), a US-based medical device company (‘Visioneering’ or ‘The Company’) engaged in the design, manufacture, sale and distribution of its proprietary NaturalVue® Multifocal 1 Day Contact Lenses, is pleased to announce the recent expansion of its US sales force. In line with Visioneering’s plan to broaden and accelerate its US launch of NaturalVue Multifocal Contact Lenses, they have appointed Mr. Joshua Suarez as new District Sales Manager for the western United States and added 10 new sales representatives across the country. Mr. Suarez has over 14 years’ experience in senior sales roles in the healthcare and medtech industries in the US. Most recently, Joshua was the Regional Business Manager at Voyce (i4C Innovations Inc.) where he built a new region and led sales and training for the start-up remote monitoring device company. Prior to this, he was the Senior Area Business Manager at Zoetis Inc. Visioneering’s Senior Vice President of Sales & Marketing, Tony Sommer stated he was delighted with the seniority and depth of experience their new hires bring to VTI. “I am confident that Joshua’s leadership skills and extensive experience will enrich VTI as we focus on building strong and long term partnerships with the eye-care industry.” Mr. Sommer continued, “There is significant interest building around the NaturalVue Multifocal. Our recent successful finance raise is enabling us to increase our sales coverage and strengthen our commercialization efforts across the country.” These new, highly-experienced sales representatives will cover Northern and Southern California (Los Angeles, San Diego, Sacramento and San Francisco), the northeast (including New York City, Long Island, upstate New York, Connecticut and New Jersey), Ohio (Cincinnati) and the Carolinas. CEO and Executive Director Dr. Stephen Snowdy said, “We plan to build out our US sales force to 45 sales representatives over the next 12 months, and we are off to a sprinting start with the addition of 11 new sales personnel.” Visioneering Technologies, Inc. (VTI), headquartered in northern Atlanta, Georgia, is an innovative company dedicated to developing products that improve vision. With a portfolio of technologies, the company uses creative and differentiated design approaches to develop products that enhance practitioner and patient experiences. VTI optical designs have been awarded nine patents worldwide, with an additional ten pending. Strength in science, an entrepreneurial culture, and the ability to bring technology to life make Visioneering Technologies, Inc. a company to watch. For more information, visit www.vtivision.com/ or call 844-884-5367, ext. 104.


News Article | May 4, 2017
Site: www.businesswire.com

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2017 and reaffirmed its guidance for full year 2017. The company reported revenue of $1.2 billion for the first quarter of 2017, an increase of 6% compared with the first quarter of 2016. Net income for the first quarter of 2017 was $238 million, or $0.48 per diluted share, an increase of 17% on a reported basis. Adjusted net income1 for the first quarter of 2017 was $261 million, or $0.53 per diluted share, an increase of 9% and 10%, respectively, on a reported basis. Adjusted net income for the first quarter of 2017 excludes the net impact of $23 million for purchase accounting adjustments, acquisition-related costs and certain significant items. On an operational2 basis, revenue for the first quarter of 2017 increased 6%, excluding the impact of foreign currency. Adjusted net income for the first quarter of 2017 increased 10% operationally, excluding the impact of foreign currency. “In the first quarter of 2017, we continue to see positive results from our diverse portfolio, innovative new companion animal products, and a more efficient cost structure,” said Juan Ramón Alaix, Chief Executive Officer at Zoetis. “Our revenue grew 6% operationally in the first quarter, driven largely by sales of companion animal products such as Simparica, Apoquel and Cytopoint, and our livestock portfolio featured growth in swine, cattle and fish across our international markets. We posted 10% operational growth in adjusted net income – once again faster than revenue growth – as we continue delivering steady profitable results.” “As costs for our one-time initiatives are largely complete, we were able to deliver 17% growth in reported EPS and continue to focus our investments on the ongoing business,” said Glenn David, Executive Vice President and Chief Financial Officer at Zoetis. “We see a good runway for continued growth, based on our diverse portfolio and recently launched products, and we are reaffirming our full-year 2017 guidance.” Zoetis organizes and manages its commercial operations across two regional segments: the United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for livestock and companion animals tailored to local trends and customer needs. In the first quarter of 2017: Zoetis continues to drive demand and strengthen its diverse portfolio through the introduction of new products, lifecycle innovations, business development initiatives, strong customer relationships and entry into new markets and technologies. In the first quarter of 2017: Zoetis reaffirmed its guidance for the full year 2017, which includes: Additional guidance on other items such as expenses and tax rate is included in the financial tables and will be discussed on the company's conference call this morning. Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review first quarter 2017 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on May 4, 2017. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com. 1 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income attributable to Zoetis and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition-related costs and certain significant items. 2 Operational revenue growth (a non-GAAP financial measure) is defined as revenue growth excluding the impact of foreign exchange. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis. Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share and operational results (which exclude the impact of foreign exchange), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliation of non-GAAP financial measures and GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com. Internet Posting of Information: We routinely post information that may be important to investors in the 'Investors' section of our website at www.zoetis.com, on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us. See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). The guidance reflects foreign exchange rates as of late April 2017. Reconciliations of 2017 reported guidance to 2017 adjusted guidance follows: Certain amounts and percentages may reflect rounding adjustments.


News Article | April 27, 2017
Site: www.businesswire.com

ZAVENTEM, Belgique--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) a annoncé aujourd’hui que la Commission européenne lui avait donné l’autorisation de mise sur le marché de Cytopoint (lokivetmab), le premier traitement par anticorps monoclonal (mAb) autorisé à des fins vétérinaires dans l’Union européenne. Cytopoint est préconisé pour le traitement des signes cliniques, dont les démangeaisons et les signes inflammatoires, associés à la dermatite atopique chez les chiens de tous âges pesant au moins 3 kg. Cytopoint cible et neutralise la cytokine canine interleukin-31 (cIL-31), protéine clé participant au déclenchement des démangeaisons chez les chiens. Administré par injection une fois par mois, Cytopoint permet de soulager rapidement et de manière durable les démangeaisons – signe principal de la dermatite atopique, allergie cutanée affectant les chiens – ainsi que l’inflammation et les lésions causées. Cytopoint permet d’améliorer à long terme la santé et la qualité de vie des chiens souffrant de dermatite atopique, tout en réduisant la frustration et l’inquiétude ressenties par leurs propriétaires. « Personnellement, l’expérience que j’ai eue de Cytopoint a confirmé une efficacité étonnamment rapide, avec une réduction considérable des démangeaisons chez les chiens dès les premières 24 heures, » a déclaré Dr. Emmanuel Bensignor, spécialiste en dermatologie vétérinaire à Paris, qui a participé aux études de terrain menées en Europe. « La dermatite atopique est une maladie très courante chez les chiens, et les propriétaires que je rencontre souhaitent trouver à tout prix une solution rapide, fiable et sûre pour alléger la souffrance de leur chien. Je pense que Cytopoint a le potentiel de répondre aux besoins des propriétaires d’animaux domestiques en raison du côté pratique de son injection mensuelle unique. Avec ce premier traitement par anticorps monoclonal à usage vétérinaire, les dermatologues vétérinaires et les vétérinaires européens pourront désormais accéder à une nouvelle classe thérapeutique. Il s’agit-là d’une innovation très prometteuse qui améliore de manière notable la santé et la qualité de vie des chiens tout en apaisant les inquiétudes de leur famille. » « Nous sommes honorés d’être les premiers à obtenir l’autorisation de la Commission européenne pour la commercialisation d’un traitement par anticorps monoclonal à usage vétérinaire », a souligné Dr. Catherine Knupp, vice-présidente exécutive et présidente de la Recherche et du Développement à Zoetis. « Avec ce traitement pionnier contre la dermatite atopique, nous utilisons une fois encore notre science et nous nous concentrons sur les défis les plus pressants de nos clients pour trouver des solutions dans un domaine où les besoins en matière de santé animale ne sont pas satisfaits. » Selon Dr. Knupp, cette innovation est le fruit d’une analyse scientifique plus approfondie pour comprendre les causes des allergies cutanées chez les chiens au niveau moléculaire et du développement, à partir de cette nouvelle approche, de traitements novateurs, ciblés et efficaces. « Les vétérinaires nous ont fait part de la diversité des besoins des chiens allergiques et de leurs propriétaires. Nous nous félicitons de pouvoir leur offrir deux solutions novatrices avec Cytopoint et notre traitement par comprimé oral, Apoquel. Ces deux médicaments de premier choix constituent pour les vétérinaires deux options efficaces et sûres leur permettant de personnaliser le traitement de la dermatite atopique de leurs patients canins. Je suis vraiment très fière de ces traitements révolutionnaires développés par l’équipe de Zoetis », a souligné Dr. Knupp. Cytopoint est une solution injectable stérile et prête à l’emploi contenant l’anticorps monoclonal mAb lokivetmab. Elle a été spécialement conçue pour cibler et neutraliser la protéine cIL-31, cytokine clé (protéine jouant un rôle important dans la communication entre cellules) qui participe au déclenchement des démangeaisons associées à la dermatite atopique chez les chiens. En imitant l’activité des anticorps naturels, cette solution se fixe de manière sélective aux IL-31 et les neutralise, interrompant ainsi le cycle des démangeaisons dont souffrent les chiens atteints de dermatite atopique. Cytopoint commence à agir dès les huit premières heures et soulage des signes cliniques associés à la dermatite atopique canine pendant un mois, permettant ainsi la cicatrisation des lésions cutanées. Les études cliniques soumises auprès de l’Agence européenne des médicaments ont montré qu’un traitement avec une dose minimum de Cytopoint de 1 mg/kg résultait en la réduction évidente et bénéfique du prurit (démangeaisons) et du niveau de gravité de la maladie selon une évaluation mesurant le degré des lésions cutanées. Ce traitement est sûr pour les chiens de tous âges, même pour ceux souffrant de maladies concomitantes, et peut être utilisé en corrélation avec de nombreux médicaments courants, y compris les vaccins. En outre, en raison de son action précise et spécifique pour cibler et neutraliser la cytokine cIL-31, il a été prouvé que ce traitement n’interférait pas avec la réponse immunitaire, à savoir qu’il ne déclenchait ni d’immunosuppression ni de réponse immunitaire accrue non désirées. Les propriétaires d’animaux domestiques se plaignent le plus souvent des démangeaisons. Celles-ci affectent environ 1 chien sur 6, pour ceux dont les propriétaires sollicitent l’aide d’un vétérinaire.1 Divers facteurs peuvent être à l’origine des démangeaisons, comme des infections, des allergies et des parasites — et environ 15 à 20 % de tous les chiens souffrant de démangeaisons présentent une dermatite atopique.1 Zoetis est la principale entreprise du secteur de la santé animale. Son objectif est d’aider au mieux ses clients et leur entreprise. Forte de plus de 60 ans d’expérience dans le domaine de la santé animale, Zoetis découvre, développe, fabrique et commercialise des vaccins et des médicaments vétérinaires, des produits diagnostiques, des tests génétiques, des équipements bioniques et propose toute une gamme de services. Commercialisant ses produits dans plus de 100 pays, Zoetis répond aux besoins des vétérinaires, des éleveurs de bétail et des personnes qui s’occupent d’animaux domestiques. L’entreprise a généré un chiffre d’affaires annuel de 4,9 milliards de dollars US en 2016 et compte environ 9 000 employés. Pour de plus amples informations, rendez-vous sur le site www.zoetis.com. Déclarations prospectives : Le présent communiqué de presse contient des déclarations prospectives qui reflètent les perspectives actuelles de Zoetis en accord avec ses perspectives ou plans commerciaux, sa performance opérationnelle ou financière future, ses attentes concernant ses produits et autres faits futurs. Les présentes déclarations ne garantissent en rien les résultats ou les actions à venir. Ces déclarations prospectives sont sujettes aux risques et aux incertitudes. Si l’un ou plusieurs de ces risques ou incertitudes se matérialisent, ou si les assomptions sous-sous-jacentes de la direction s’avèrent inexactes, les résultats concrets peuvent différer matériellement de ceux envisagés dans une déclaration prospective. Les déclarations prospectives sont uniquement valides à la date de leur énonciation. Zoetis ne s’engage aucunement à mettre à jour ni à réviser de telles déclarations prospectives, que ce soit suite à de nouvelles informations, d’évènements futurs ou autres. Une liste et une description plus détaillées des risques, des incertitudes et autres points relatifs sont disponible dans notre Rapport annuel sur le Formulaire 10-K de l’année fiscale qui s’est terminée au samedi 31 décembre 2016, y compris dans les sections connexes intitulées « Forward-Looking Statements and Factors That May Affect Future Results » (« Déclarations prospectives et facteurs pouvant affecter les résultats futurs ») et « Item 1A. Risk Factors » (« Article 1A. Facteurs de risques »), consultables dans nos Rapports trimestriels sur le Formulaire 10-Q et dans nos Rapports en cours sur le Formulaire 8-K. Ces dossiers comme ceux à venir sont disponibles en ligne à www.sec.gov, www.zoetis.com, ou sur demande auprès de Zoetis.


Sarasota, FL, April 21, 2017 (GLOBE NEWSWIRE) -- Zion Market Research, the market research group announced the analysis report titled "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021". The study concludes that the global veterinary vaccine market is expected to grow at a CAGR of 9.3% between 2016 and 2021. The market revenue of $12.10 billion in 2015 is expected to grow up to $20.60 billion by 2021. Vaccination is one of the most used applications of modern biotechnology to prevent chronic bacterial, viral and protozoal diseases. Veterinary vaccines are eco-friendly and used to increase animal welfare by preventing the death of animals, loss of dairy products and monetary loss of owners. Recently highly effective third generation vaccine against rabies virus has been developed with the help of recombinant technology. With the use of the vaccine, we can avoid the problem of antibiotic and drug resistance by the microorganism. Browse through 10 Market Tables and 39 Figures spread through 110 Pages and in-depth TOC on “Global Veterinary Vaccine Market: By Product, Type, Technology, Regions, Poultry, Diseases, Size, Share, Industry Trends, Segments, and Forecast 2015-2021”. Major factors responsible for the growth of veterinary vaccines market include increasing pet ownership, increasing awareness for food security and increasing investment by various government agencies. Increased veterinary research institutions and colleges are also adding value to veterinary vaccines market. However, rising maintenance cost of vaccine storage and prevalence of chronic disease of animals with continuous economic slowdown are hindering the growth of the market. Increasing demand for milk, eggs, meat & animal protein and investment by the government would represent the massive opportunity in future. On the basis of product type, the market of veterinary vaccines is bifurcated into livestock vaccines and companion vaccines. Livestock vaccines account the larger market share of more than 62% and companion vaccines accounts for around 38% share of global veterinary vaccine market. Livestock vaccines segment is classified into poultry, porcine and aquaculture vaccine type. The porcine vaccine is largest sub-segment with more than 30% share of global livestock market and it is expected to remain dominant during the forecast period. Companion vaccine is segmented into equine, canine and feline.  Among these three segments, canine segments are the fastest growing segment with approximately 6% growth rate. Browse the full "Veterinary Vaccine Market by Application (Livestock Vaccines and Companion Vaccines), by Technology Types (Attenuated Vaccines, DNA Vaccines, Inactivated Vaccines, Toxoid Vaccines and Recombinant Vaccines) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2015 – 2021" report at https://www.zionmarketresearch.com/report/veterinary-vaccine-market On the basis of technology type, the veterinary vaccines market is classified into attenuated vaccines, DNA Vaccines, inactivated vaccines, toxoid vaccines, and recombinant vaccines.  With noticeable share, DNA, and attenuated vaccine segments were accounted highest growth for veterinary vaccine market in 2015. The veterinary vaccine market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. As a result of increasing demand for livestock veterinary vaccines, North America and Europe has the strong hold on veterinary vaccine market with more than 68% share. In North America, the U.S. and Canada are two major markets, while the U.S. market is expected to remain dominant with nearly 38% share in forecast period due to increasing pet ownership and growing demand for dairy products. Asia-Pacific is expected to show noticeable growth in forecast period as a result of strong demand from China and India. Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/veterinary-vaccine-market Key operating players for the veterinary vaccines market are Heska Corporation, Zoetis Inc., Ceva Santé Animale Inc., Merck Animal Health, Sanofi (Merial Animal Health), Boehringer Ingelheim GmbH, Eli Lilly and Company (Elanco Animal Health), Virbac, Bayer AG, and Bimeda. Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually. Read this entire press release and more news for PetLife Pharmaceuticals at http://www.marketnewsupdates.com/news/ptlf.html. PetLife's new patent-pending formulation has created a 'cancer cocktail' combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease to have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing recommended for the treatment of both neoplastic (cancer) and infectious disease. The 'HIV Cocktail,' which changed the world approach to the treatment of HIV, is a similar approach comparison. PetLife's new 'cancer cocktail' may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife's new 'cancer cocktail' has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient. "Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical's new product portfolio, VitalzulTM., a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets," stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company. "This ground-breaking, patent pending biotechnology will serve as the core ingredient in our pharma product Vitalzul™ once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application, and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders," added Dr. Salvagno. In other industry developments and market activity of note: MSD Animal Health (known as Merck Animal Health in the USA and Canada) yesterday announced the European launch of Time to Vaccinate, a new program designed to help farmers better appreciate the benefits of vaccinating their cattle. Vaccinations, as part of an overall prevention program, can greatly contribute to the reduction in severity and frequency of infectious diseases, including the need for some medicines, like antibiotics, to treat infections. Merck Animal Health is a subsidiary of Merck and Co. Inc. (NYSE: MRK). Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), late last month announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries. The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda and Tanzania. PetMed Express, Inc. (NASDAQ: PETS) closed up slightly on Tuesday at $36.41 by the market close. PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes. Rob Wright, Chief Editor of Life Science Leader, published an article last week addressing "Why Would Human Health Companies Want To Partner With Zoetis?" When Zoetis Inc. (NYSE: ZTS), the former animal health business unit of Pfizer Inc. (NYSE: PFE), was spun off as an independent company via an IPO in February 2013 (see Life Science Leader magazine's June 2017 cover feature), overnight it became the world's largest publically traded animal health company. And while no longer part of one of the largest human health companies in the world, this doesn't mean that a company focused on developing products just for animals isn't interested in collaborating with biopharmas dedicated to creating therapeutics for people. Scott Brown, D.V.M., Ph.D., is the executive responsible for brokering such collaborations. The VP of external innovation elaborates on some of the challenges faced by Zoetis post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal-health-focused company like Zoetis. Read the entire article at: https://www.lifescienceleader.com/doc/why-would-human-health-companies-want-to-partner-with-zoetis-0001. DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated four thousand three hundred dollars for news coverage of the current press release issued by PetLife Pharmaceuticals, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.


PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually. Read this entire press release and more news for PetLife Pharmaceuticals at http://www.marketnewsupdates.com/news/ptlf.html. PetLife's new patent-pending formulation has created a 'cancer cocktail' combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease to have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing recommended for the treatment of both neoplastic (cancer) and infectious disease. The 'HIV Cocktail,' which changed the world approach to the treatment of HIV, is a similar approach comparison. PetLife's new 'cancer cocktail' may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife's new 'cancer cocktail' has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient. "Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical's new product portfolio, VitalzulTM., a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets," stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company. "This ground-breaking, patent pending biotechnology will serve as the core ingredient in our pharma product Vitalzul™ once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application, and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders," added Dr. Salvagno. In other industry developments and market activity of note: MSD Animal Health (known as Merck Animal Health in the USA and Canada) yesterday announced the European launch of Time to Vaccinate, a new program designed to help farmers better appreciate the benefits of vaccinating their cattle. Vaccinations, as part of an overall prevention program, can greatly contribute to the reduction in severity and frequency of infectious diseases, including the need for some medicines, like antibiotics, to treat infections. Merck Animal Health is a subsidiary of Merck and Co. Inc. (NYSE: MRK). Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), late last month announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries. The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda and Tanzania. PetMed Express, Inc. (NASDAQ: PETS) closed up slightly on Tuesday at $36.41 by the market close. PetMed Express, Inc. and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats to retail customers. It provides non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, thyroid, diabetes, pain medications, antibiotics, and other specialty medications, as well as generic substitutes. Rob Wright, Chief Editor of Life Science Leader, published an article last week addressing "Why Would Human Health Companies Want To Partner With Zoetis?" When Zoetis Inc. (NYSE: ZTS), the former animal health business unit of Pfizer Inc. (NYSE: PFE), was spun off as an independent company via an IPO in February 2013 (see Life Science Leader magazine's June 2017 cover feature), overnight it became the world's largest publically traded animal health company. And while no longer part of one of the largest human health companies in the world, this doesn't mean that a company focused on developing products just for animals isn't interested in collaborating with biopharmas dedicated to creating therapeutics for people. Scott Brown, D.V.M., Ph.D., is the executive responsible for brokering such collaborations. The VP of external innovation elaborates on some of the challenges faced by Zoetis post IPO in creating research collaborations, as well as why human-health oriented companies might want to consider collaborating with an animal-health-focused company like Zoetis. Read the entire article at: https://www.lifescienceleader.com/doc/why-would-human-health-companies-want-to-partner-with-zoetis-0001. DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated four thousand three hundred dollars for news coverage of the current press release issued by PetLife Pharmaceuticals, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Loading Zoetis Inc. collaborators
Loading Zoetis Inc. collaborators